Drug delivery techniques for treating age-related macular degeneration. - Wikidata - awgldk - TriplyDB

Drug delivery techniques for treating age-related macular degeneration.

Drug delivery techniques for treating age-related macular degeneration.

http://www.wikidata.org/entity/Q38161953

about

Management of neovascular age-related macular degeneration: current state-of-the-art care for optimizing visual outcomes and therapies in development Sustained Delivery of Bioactive GDNF from Collagen and Alginate-Based Cell-Encapsulating Gel Promoted Photoreceptor Survival in an Inherited Retinal Degeneration Model Injectable Chemically Crosslinked Hydrogel for the Controlled Release of Bevacizumab in Vitreous: A 6-Month In Vivo Study Emerging drugs for diabetic macular edema.Cubosomes and other potential ocular drug delivery vehicles for macromolecular therapeutics.Light-responsive in situ forming injectable implants for effective drug delivery to the posterior segment of the eye.Lipid-based drug delivery systems in the treatment of wet age-related macular degeneration.Solid Lipid Nanoparticles Improve the Diclofenac Availability in Vitreous after Intraocular Injection Delivery of therapeutics to posterior eye segment: cell-encapsulating systems Sustaining Intravitreal Residence With L-Arginine Peptide-Conjugated Nanocarriers.Ciliary neurotrophic factor (CNTF) delivery to retina: an overview of current research advancements.

P2860

Q26824335-70979DA8-A2AF-4F41-BC84-E508A6C8CA3B Q28552762-848F0BDA-0B9E-4C12-826E-4979A0DDF2A1 Q35166714-506911A6-5072-4389-8387-2BED9C779346 Q38241679-380C97E1-1451-4943-BFAC-04D4CD8AFF3C Q38368715-2027B431-5AD2-48EC-8305-D5A0DF39992B Q38769853-4317E1C7-5AF6-4D4F-A1D2-74CDCE9C4087 Q38837906-C97C961A-81A8-4EC3-A380-56D2210F6CD0 Q41543242-08DC7303-35BA-4E36-B991-B2C7E3F02812 Q41994586-9CE55006-DB49-4A14-B3A6-75B57174BC4D Q42373794-E0BC1EDF-022E-4246-A686-5DDCFB4FDA09 Q47601916-87CE1ABC-2076-4910-8F08-206DD15EF2FD

P2860

Drug delivery techniques for treating age-related macular degeneration.

http://www.wikidata.org/entity/Q38161953

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

Drug delivery techniques for treating age-related macular degeneration.

@en

type

label

Drug delivery techniques for treating age-related macular degeneration.

@en

prefLabel

Drug delivery techniques for treating age-related macular degeneration.

@en

P1433

Q38161953-13DE2435-79FF-4995-87CA-32B80CC165EA

P1476

Q38161953-C836BD59-3CF9-4200-9623-3F92371C449E

P2093

Q38161953-34B86969-5AA8-40D5-9C0F-62D83E53CDE7

Q38161953-528003DA-8F85-4CAF-9611-64A1DC5B50FA

Q38161953-A394D3D3-B6B8-4F2A-B06B-47A27016962F

Q38161953-CF495497-C018-4BC8-9910-76CDF0C2BFDE

P2860

Q38161953-0A02A32E-E67E-430F-8451-13BF19A7B47B

Q38161953-0C4A084D-AF56-4ECF-83AB-A211AB19B48D

Q38161953-14A496CA-D41A-49B5-B3E5-9C99BDED29A0

Q38161953-1EA510E9-B76F-4DF0-9875-8F280575A322

Q38161953-1EC71A54-316F-4955-A288-CEFF33B91B6D

Q38161953-216B3A9C-6FCF-45A8-B5A8-4B2D8958C8D0

Q38161953-22FCC6BB-77D4-428A-B119-9B08800870F1

Q38161953-329040B6-A9DB-4C89-B26D-F924BA83666C

Q38161953-38C625B6-E777-42A0-8F42-B6AEC917329E

Q38161953-3B6442B6-D6D0-49A1-A997-BF0793C49D97

P304

Q38161953-ECCD4BFF-AB3E-4ECF-9A92-EA840D8F4ADC

P31

Q38161953-01B2584F-0601-410F-9223-ED66015F88EB

P356

Q38161953-EE270D10-6115-425B-8FC8-AB63308E7337

P407

Q38161953-54E0269E-E5C8-4A0B-8B6B-D0BBA39B0D2B

P433

Q38161953-554E91A4-A8D1-41FF-9D52-BF0890A607D9

P478

Q38161953-D24C584F-777C-43B5-9F2B-9C717AB7BBA4

P577

Q38161953-940F20D2-2440-438B-B516-4FE4C3EEE1D3

P5875

Q38161953-853E993A-76E2-4AE4-9579-3D19A276CBAC

P698

Q38161953-10A6621C-79B4-482B-9C5A-EE864CA6E734

P921

Q38161953-6484F892-B503-4A25-BB32-2742EF1660B6

P356

17425247.2013.859135

P1433

Expert Opinion on Drug Delivery

P1476

Drug delivery techniques for treating age-related macular degeneration.

@en

P2093

Harry W Flynn

http://www.w3.org/2001/XMLSchema#string

Ingrid U Scott

http://www.w3.org/2001/XMLSchema#string

Michael W Stewart

http://www.w3.org/2001/XMLSchema#string

Stephen G Schwartz

http://www.w3.org/2001/XMLSchema#string

P2860

Ranibizumab and bevacizumab for neovascular age-related macular degeneration

Liposomes and nanotechnology in drug development: focus on ocular targets

Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial

Ranibizumab for neovascular age-related macular degeneration

Targeted administration into the suprachoroidal space using a microneedle for drug delivery to the posterior segment of the eye

Endogenous VEGF is required for visual function: evidence for a survival role on müller cells and photoreceptors

Suppression of choroidal neovascularization by intravitreal injection of liposomal SU5416.

Comparison of long-acting bevacizumab formulations in the treatment of choroidal neovascularization in a rat model.

Micro-patterned drug delivery device for light-activated drug release.

Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co-glycolic)acid microspheres.

P304

61-68

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/17425247.2013.859135

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2013-11-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258500838

http://www.w3.org/2001/XMLSchema#string

P698

24219407

http://www.w3.org/2001/XMLSchema#string

P921